Examination of usefulness and safety of heparinoid agent based external medicine (over counter drug) for facial dryness symptom.

Examination of usefulness and safety of heparinoid agent based external medicine (over counter drug) for facial dryness symptom. - Usefulness of heparinoid agent based external medicine for facial dryness symptom.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000018986

Enrollment

Registered

2015-09-30

Start date

2015-11-12

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

facial dryness symptom

Interventions

Test medicine is used for right face, and placebo medicine is used for left face, for 4 weeks twice a day. Placebo medicine is used for right face, and test medicine is used for left face, for 4 weeks

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: The person who fells facail dryness symptom.

Exclusion criteria

Exclusion criteria: The person 1. Who takes in an oral pharmaceutical product or a supplement which may affect the skin condition habitually. 2. Who had the anamnestic history of surgical operation on the testing area. 3. Who is infected with hemorrhagic disease. 4. Who has skin rash of atopic dermatitis on face. 5. Who uses regularly an external medicine. 6. Who had the anamnesis of heparinoid allergy. 7. Who has allergy or sensitivity to drug and cosmetics. 8. Who can not agree that using same cosmetics all over the study time. 9. Who has skin disease on the testing area. 10. Who has the factor on the testing area which may affect the result. 11. Who has critical illness of glucose metabolism, lipid metabolism, liver function, renal function, cardiovascular system, respiratory tract, endocrine system, immune system and nervous system, or had the anamnestic history of psychiatric disorder. 12. Who can not understand about examination contents. 13. Who is pregnant or lactating. 14. Who is impossible to come to the testing institution on an examination day. 15. Who participates in other examinations. 16. Who is recognized to be inappropriate as a subject by attending physician.

Design outcomes

Primary

Measure	Time frame
At the time of strating, 2 weeks later and 4 weeks later. The measurement of a. Wrinkle and pigmented spot. b. Moisture content of the stratum corneum. c. Transepidermal water loss. d. Skin elasticity. e. Tape stripping of corneocyte.	—

Secondary

Measure	Time frame
Change of the subjective symptoms of the subject.	—

Countries

Japan

Contacts

Public ContactDaisuke Tsuruta

Osaka city university graduate school of medicine department of dermatology

dtsuruta@med.osaka-cu.ac.jp06-6645-3826

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026